NuVasive 's fortunes are bound to spinal fusion.
NuVasive ( NUVA ): Q1 EPS of $0.26 beats by $0.04 . Revenue of $159.5M (+5.2% Y/Y) beats by $2.06M . ( PR ) Post your comment!
treatment. Additionally, smaller competitors such as NuVasive NUVA have introduced new biologic products that compete with ..... be bundled with its hardware and instrument systems, NuVasive has been able to attract more spinal surgeons to embrace
We are no longer providing equity research on NuVasive NUVA . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
NuVasive NUVA announced its intentions to issue $325 ..... issue. In terms of valuation, we think NuVasive shares are about fairly valued, so we ..... a potential credit-sensitive play at NuVasive . We've seen 10-year issues of BBB
NuVasive NUVA reported fourth-quarter earnings that ..... commercial insurers still provide coverage for NuVasive 's lateral procedure though, after deeming ..... and long-term assumptions. We think NuVasive will have to largely generate growth in
We are placing NuVasive NUVA under review as we update our valuation. As we noted previously, we will moderately cut our fair value estimate due to a decrease
NuVasive NUVA reported disappointing projections for ..... fourth quarter, which traditionally is NuVasive 's strong quarter. We will lower our ..... moderate cut in our fair value estimate. NuVasive posted decent third-quarter results
NuVasive NUVA put in a strong second quarter and increased ..... margin biologics and international sales. NuVasive 's operating expenses climbed to $90 ..... of 29% over the prior-year period. NuVasive invested heavily in expanding its international
initiating our issuer credit rating for NuVasive NUVA at BBB - , reflecting its improving ..... position and cash flow trends . NuVasive 's Maximum Access Surgery platform ..... new approach , so far . In fact , NuVasive has carved out a nice niche in